Novartis AG (NVS) Smoker's Cough Treatment Beats GlaxoSmithKline (GSK)'s Advair in Trial  
8/29/2012 7:29:15 AM

Patients taking Novartis AG (NOVN)’s experimental once-daily treatment for smoker’s cough showed a significant improvement in lung function over those on an existing medicine marketed by GlaxoSmithKline Plc (GSK), which is also developing a successor drug. Patients taking Novartis’s QVA149 were able to expel 100 milliliters (3.4 ounces) more air from their lungs in one second than those receiving Glaxo’s best-selling Advair after 26 weeks of treatment, according to a summary of data from a trial dubbed “Illuminate” to be presented at the European Respiratory Society annual meeting next week.